Structure Therapeutics CSO sells 5,939 ADSs

Structure Therapeutics’ chief scientific officer exercised options and sold 5,939 ADSs under a pre-arranged Rule 10b5-1 trading plan.

Rhea-AI Filing Summary

Structure Therapeutics Inc. (GPCR) reported that its Chief Scientific Officer, Xichen Lin, exercised options for 17,817 Ordinary Shares at an exercise price of $0.34 per share on September 1, 2026, leaving 125,081 Ordinary Shares subject to the option.

The 17,817 Ordinary Shares were converted into 5,939 American Depositary Shares (ADSs), each ADS representing three Ordinary Shares, and all 5,939 ADSs were sold in multiple transactions at weighted average prices of $45.8642 and $47.2030 per ADS. The ADS sales were made under a Rule 10b5-1 trading plan entered into on March 26, 2026.

Insider Trade Summary 10b5-1

Net Seller: 5,939 shares

Net Sell 7 txns

Insider Lin Xichen

Role CHIEF SCIENTIFIC OFFICER

Sold 5,939 shs ($279K)

Type	Security	Shares	Price	Value
Exercise	Share Option (right to buy) F1, F3, F4	17,817	$0.00	$0.00
Conversion	American Depositary Shares F5, F6	5,939	$0.00	$0.00
Sale	American Depositary Shares F5, F7, F8, F9	1,300	$45.8642	$60K
Sale	American Depositary Shares F5, F7, F8, F10	4,539	$47.203	$214K
Sale	American Depositary Shares F5, F7, F8	100	$47.83	$5K
Exercise	Ordinary Shares F1	17,817	$0.34	$6K
Conversion	Ordinary Shares F2	17,817	$0.00	$0.00

Holdings After Transaction: Share Option (right to buy) — 125,081 contracts (Direct); American Depositary Shares — 0 contracts (Direct); Ordinary Shares — 228,960 shares (Direct)

Footnotes (10)

1. F1. Reflects price per share in Ordinary Shares.
2. F2. The Ordinary Shares were converted into American Depositary Shares as reported in Table II.
3. F3. 1/4 of the Ordinary Shares vested one year after July 22, 2019 (the "Vesting Commencement Date"); the balance of the Ordinary Shares vested in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.
4. F4. This reflects the number of Ordinary Shares remaining under the share option following the partial exercise of the share option for 17,817 Ordinary Shares.
5. F5. Each American Depositary Share is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The American Depositary Shares have no expiration date.
6. F6. 17,817 Ordinary Shares, which were acquired upon exercise of a share option, were converted into 5,939 American Depositary Shares.
7. F7. The American Depositary Shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 26, 2026.
8. F8. Reflects price per share in American Depositary Shares.
9. F9. The weighted average sale price for the transaction reported was $45.8642 and the range of prices were between $45.63 and $46.38. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of American Depositary Shares sold at each price will be provided.
10. F10. The weighted average sale price for the transaction reported was $47.2030, and the range of prices were between $46.80 and $47.76. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of American Depositary Shares sold at each price will be provided.

Key Figures

Options exercised: 17,817 Ordinary Shares Option exercise price: $0.34 per Ordinary Share Remaining option shares: 125,081 Ordinary Shares +5 more

8 metrics

Options exercised 17,817 Ordinary Shares Share option exercise on September 1, 2026

Option exercise price $0.34 per Ordinary Share Exercise of share option for 17,817 Ordinary Shares

Remaining option shares 125,081 Ordinary Shares Ordinary Shares remaining under option after partial exercise

ADSs received on conversion 5,939 ADSs 17,817 Ordinary Shares converted into ADSs

ADSs sold 5,939 ADSs Total ADSs sold in three transactions on September 1, 2026

Sale price (weighted average 1,300 ADSs lot) $45.8642 per ADS Weighted average sale price with range $45.63–$46.38

Sale price (weighted average 4,539 ADSs lot) $47.2030 per ADS Weighted average sale price with range $46.80–$47.76

ADS-to-Ordinary conversion ratio 1 ADS : 3 Ordinary Shares Each ADS convertible into three Ordinary Shares, no expiration date

Key Terms

Rule 10b5-1 trading plan, American Depositary Shares, share option, weighted average sale price

4 terms

Rule 10b5-1 trading plan regulatory

"The American Depositary Shares were sold pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

American Depositary Shares financial

"Each American Depositary Share is convertible at any time, at the holder's election"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

share option financial

"This reflects the number of Ordinary Shares remaining under the share option following"

weighted average sale price financial

"The weighted average sale price for the transaction reported was $45.8642"

FAQ

What did GPCR’s Chief Scientific Officer report in this Form 4?

The Chief Scientific Officer, Xichen Lin, exercised options for 17,817 Ordinary Shares, converted them into 5,939 ADSs, and sold all 5,939 ADSs in market transactions on September 1, 2026, while retaining 125,081 Ordinary Shares under the option.

How many Structure Therapeutics (GPCR) shares did the insider sell and at what prices?

Xichen Lin sold 5,939 ADSs of Structure Therapeutics in three transactions: 1,300 ADSs at a weighted average price of $45.8642, 4,539 ADSs at $47.2030, and 100 ADSs at $47.83 per ADS, all on September 1, 2026.

Were the GPCR insider sales made under a Rule 10b5-1 trading plan?

Yes. The filing states the American Depositary Shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 26, 2026, and the plan-status checkbox indicating Rule 10b5-1 reliance is affirmed.

What options did the GPCR insider exercise in this transaction?

Xichen Lin exercised a share option for 17,817 Ordinary Shares at an exercise price of $0.34 per share. After this partial exercise, 125,081 Ordinary Shares remained subject to the option, which expires on September 10, 2029.

How are Structure Therapeutics (GPCR) ADSs related to Ordinary Shares?

Each American Depositary Share of Structure Therapeutics is convertible at any time, at the holder’s election, into three Ordinary Shares. The filing also notes that the ADSs have no expiration date.

What is the net effect of this Form 4 on the GPCR insider’s position?

The filing shows a net sale of 5,939 ADSs following the exercise and conversion of options. The insider also continues to hold 125,081 Ordinary Shares under the remaining unexercised portion of the share option reported.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 09:19 PM Accepted by SEC EDGAR 09/02/2026 - 09:18 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lin Xichen

(Last) (First) (Middle)

C/O STRUCTURE THERAPEUTICS INC.

601 GATEWAY BLVD., SUITE 900

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Structure Therapeutics Inc. [ GPCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF SCIENTIFIC OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	09/01/2026		M		17,817	A	$0.34(1)	246,777	D
Ordinary Shares	09/01/2026		C		17,817(2)	D	$0	228,960	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)	$0.34(1)	09/01/2026		M			17,817	(3)	09/10/2029	Ordinary Shares	17,817	$0	125,081(4)	D
American Depositary Shares	(5)	09/01/2026		C		5,939(6)		(5)	(5)	Ordinary Shares	5,939	$0	5,939	D
American Depositary Shares	(5)	09/01/2026		S(7)			1,300	(5)	(5)	Ordinary Shares	1,300	$45.8642(8)(9)	4,639	D
American Depositary Shares	(5)	09/01/2026		S(7)			4,539	(5)	(5)	Ordinary Shares	4,539	$47.203(8)(10)	100	D
American Depositary Shares	(5)	09/01/2026		S(7)			100	(5)	(5)	Ordinary Shares	100	$47.83(8)	0	D

Explanation of Responses:

1. Reflects price per share in Ordinary Shares.

2. The Ordinary Shares were converted into American Depositary Shares as reported in Table II.

3. 1/4 of the Ordinary Shares vested one year after July 22, 2019 (the "Vesting Commencement Date"); the balance of the Ordinary Shares vested in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.

4. This reflects the number of Ordinary Shares remaining under the share option following the partial exercise of the share option for 17,817 Ordinary Shares.

5. Each American Depositary Share is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The American Depositary Shares have no expiration date.

6. 17,817 Ordinary Shares, which were acquired upon exercise of a share option, were converted into 5,939 American Depositary Shares.

7. The American Depositary Shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 26, 2026.

8. Reflects price per share in American Depositary Shares.

9. The weighted average sale price for the transaction reported was $45.8642 and the range of prices were between $45.63 and $46.38. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of American Depositary Shares sold at each price will be provided.

10. The weighted average sale price for the transaction reported was $47.2030, and the range of prices were between $46.80 and $47.76. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of American Depositary Shares sold at each price will be provided.

	/s/ Jun Yoon, Attorney-in-Fact	09/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)